Discovery and validation of a serologic autoantibody panel for early diagnosis of esophageal squamous cell carcinoma

Jianbo Pan, Qing Zhu Zheng, Yadong Li, Li Li Yu, Qing Wei Wu, Jia Ying Zheng, Xiao Jie Pan, Bao Song Xie, Yan An Wu, Jiang Qian, Heng Zhu, Yi Huang

Research output: Contribution to journalArticle

Abstract

Background: Esophageal squamous cell carcinoma (ESCC) accounts for the highest incidence rate worldwide and is responsible for the fourth leading cause of cancer-related death. Currently, serologic biomarkers for early ESCC diagnosis are needed for timely treatment. Methods: The performance of a four-autoantibody panel (i.e., anti-TP53, HRAS, CTAG1A, and NSG1) was evaluated by ELISA for the early diagnosis of ESCC with 569 retrospective serum samples. A training set comprising 129 patients with early-stage ESCC, 130 patients with esophageal benign lesion (EBL), and 150 healthy controls (HC) was used to develop an early ESCC predictive model. Data obtained from an independent validation set were used to evaluate and validate the predictive model to distinguish the early ESCC from the controls (EBLþHC). Finally, a multiplexed assay based on the Luminex xMAP technology platform was developed to enable simultaneous detection of the four-autoantibody panel using the validation set. Results: The four-autoantibody panel significantly discriminated early ESCC cases from the controls with 62.8% sensitivity at 88.9% specificity in the training set and with 58.0% sensitivity at 90.0% specificity in the independent validation set. The results of the multiplexed assay using xMAP technology for early ESCC showed a significant correlation with that of the ELISA assays with 66.0% sensitivity at 90.9% specificity. Conclusions: A four-autoantibody panel showed good performance for early ESCC diagnosis with ELISA and could be further developed into a multiplex assay using the Luminex xMAP technology. Impact: The four-autoantibody panel could be used for serologic screening for early ESCC.

Original languageEnglish (US)
Pages (from-to)1454-1460
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume28
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Autoantibodies
Early Diagnosis
Enzyme-Linked Immunosorbent Assay
Technology
Esophageal Squamous Cell Carcinoma
Biomarkers
Incidence
Serum

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Discovery and validation of a serologic autoantibody panel for early diagnosis of esophageal squamous cell carcinoma. / Pan, Jianbo; Zheng, Qing Zhu; Li, Yadong; Yu, Li Li; Wu, Qing Wei; Zheng, Jia Ying; Pan, Xiao Jie; Xie, Bao Song; Wu, Yan An; Qian, Jiang; Zhu, Heng; Huang, Yi.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 28, No. 9, 01.09.2019, p. 1454-1460.

Research output: Contribution to journalArticle

Pan, Jianbo ; Zheng, Qing Zhu ; Li, Yadong ; Yu, Li Li ; Wu, Qing Wei ; Zheng, Jia Ying ; Pan, Xiao Jie ; Xie, Bao Song ; Wu, Yan An ; Qian, Jiang ; Zhu, Heng ; Huang, Yi. / Discovery and validation of a serologic autoantibody panel for early diagnosis of esophageal squamous cell carcinoma. In: Cancer Epidemiology Biomarkers and Prevention. 2019 ; Vol. 28, No. 9. pp. 1454-1460.
@article{c4504d47d7954a59a6528f0986da2a0b,
title = "Discovery and validation of a serologic autoantibody panel for early diagnosis of esophageal squamous cell carcinoma",
abstract = "Background: Esophageal squamous cell carcinoma (ESCC) accounts for the highest incidence rate worldwide and is responsible for the fourth leading cause of cancer-related death. Currently, serologic biomarkers for early ESCC diagnosis are needed for timely treatment. Methods: The performance of a four-autoantibody panel (i.e., anti-TP53, HRAS, CTAG1A, and NSG1) was evaluated by ELISA for the early diagnosis of ESCC with 569 retrospective serum samples. A training set comprising 129 patients with early-stage ESCC, 130 patients with esophageal benign lesion (EBL), and 150 healthy controls (HC) was used to develop an early ESCC predictive model. Data obtained from an independent validation set were used to evaluate and validate the predictive model to distinguish the early ESCC from the controls (EBL{\th}HC). Finally, a multiplexed assay based on the Luminex xMAP technology platform was developed to enable simultaneous detection of the four-autoantibody panel using the validation set. Results: The four-autoantibody panel significantly discriminated early ESCC cases from the controls with 62.8{\%} sensitivity at 88.9{\%} specificity in the training set and with 58.0{\%} sensitivity at 90.0{\%} specificity in the independent validation set. The results of the multiplexed assay using xMAP technology for early ESCC showed a significant correlation with that of the ELISA assays with 66.0{\%} sensitivity at 90.9{\%} specificity. Conclusions: A four-autoantibody panel showed good performance for early ESCC diagnosis with ELISA and could be further developed into a multiplex assay using the Luminex xMAP technology. Impact: The four-autoantibody panel could be used for serologic screening for early ESCC.",
author = "Jianbo Pan and Zheng, {Qing Zhu} and Yadong Li and Yu, {Li Li} and Wu, {Qing Wei} and Zheng, {Jia Ying} and Pan, {Xiao Jie} and Xie, {Bao Song} and Wu, {Yan An} and Jiang Qian and Heng Zhu and Yi Huang",
year = "2019",
month = "9",
day = "1",
doi = "10.1158/1055-9965.EPI-18-1269",
language = "English (US)",
volume = "28",
pages = "1454--1460",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Discovery and validation of a serologic autoantibody panel for early diagnosis of esophageal squamous cell carcinoma

AU - Pan, Jianbo

AU - Zheng, Qing Zhu

AU - Li, Yadong

AU - Yu, Li Li

AU - Wu, Qing Wei

AU - Zheng, Jia Ying

AU - Pan, Xiao Jie

AU - Xie, Bao Song

AU - Wu, Yan An

AU - Qian, Jiang

AU - Zhu, Heng

AU - Huang, Yi

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Background: Esophageal squamous cell carcinoma (ESCC) accounts for the highest incidence rate worldwide and is responsible for the fourth leading cause of cancer-related death. Currently, serologic biomarkers for early ESCC diagnosis are needed for timely treatment. Methods: The performance of a four-autoantibody panel (i.e., anti-TP53, HRAS, CTAG1A, and NSG1) was evaluated by ELISA for the early diagnosis of ESCC with 569 retrospective serum samples. A training set comprising 129 patients with early-stage ESCC, 130 patients with esophageal benign lesion (EBL), and 150 healthy controls (HC) was used to develop an early ESCC predictive model. Data obtained from an independent validation set were used to evaluate and validate the predictive model to distinguish the early ESCC from the controls (EBLþHC). Finally, a multiplexed assay based on the Luminex xMAP technology platform was developed to enable simultaneous detection of the four-autoantibody panel using the validation set. Results: The four-autoantibody panel significantly discriminated early ESCC cases from the controls with 62.8% sensitivity at 88.9% specificity in the training set and with 58.0% sensitivity at 90.0% specificity in the independent validation set. The results of the multiplexed assay using xMAP technology for early ESCC showed a significant correlation with that of the ELISA assays with 66.0% sensitivity at 90.9% specificity. Conclusions: A four-autoantibody panel showed good performance for early ESCC diagnosis with ELISA and could be further developed into a multiplex assay using the Luminex xMAP technology. Impact: The four-autoantibody panel could be used for serologic screening for early ESCC.

AB - Background: Esophageal squamous cell carcinoma (ESCC) accounts for the highest incidence rate worldwide and is responsible for the fourth leading cause of cancer-related death. Currently, serologic biomarkers for early ESCC diagnosis are needed for timely treatment. Methods: The performance of a four-autoantibody panel (i.e., anti-TP53, HRAS, CTAG1A, and NSG1) was evaluated by ELISA for the early diagnosis of ESCC with 569 retrospective serum samples. A training set comprising 129 patients with early-stage ESCC, 130 patients with esophageal benign lesion (EBL), and 150 healthy controls (HC) was used to develop an early ESCC predictive model. Data obtained from an independent validation set were used to evaluate and validate the predictive model to distinguish the early ESCC from the controls (EBLþHC). Finally, a multiplexed assay based on the Luminex xMAP technology platform was developed to enable simultaneous detection of the four-autoantibody panel using the validation set. Results: The four-autoantibody panel significantly discriminated early ESCC cases from the controls with 62.8% sensitivity at 88.9% specificity in the training set and with 58.0% sensitivity at 90.0% specificity in the independent validation set. The results of the multiplexed assay using xMAP technology for early ESCC showed a significant correlation with that of the ELISA assays with 66.0% sensitivity at 90.9% specificity. Conclusions: A four-autoantibody panel showed good performance for early ESCC diagnosis with ELISA and could be further developed into a multiplex assay using the Luminex xMAP technology. Impact: The four-autoantibody panel could be used for serologic screening for early ESCC.

UR - http://www.scopus.com/inward/record.url?scp=85071787190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071787190&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-18-1269

DO - 10.1158/1055-9965.EPI-18-1269

M3 - Article

C2 - 31239266

AN - SCOPUS:85071787190

VL - 28

SP - 1454

EP - 1460

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 9

ER -